LMB 763

Drug Profile

LMB 763

Alternative Names: LMB-763

Latest Information Update: 23 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Hepatoprotectants
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Preclinical Cholestasis

Most Recent Events

  • 19 Jun 2017 Phase-II clinical trials in Non-alcoholic steatohepatitis in Georgia, Jordan, New Zealand, United Kingdom (PO) (NCT02913105)
  • 19 Apr 2017 Adverse events, pharmacokinetics and pharmacodynamics data from a first-in-human trial in Non-alcoholic steatohepatitis presented at the The International Liver Congress 2017 (ILC-2017)
  • 19 Apr 2017 Pharmacodynamics data from a preclinical study in Non-alcoholic steatohepatitis and Cholestasis presented at the International Liver Congress 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top